Clinical trials
Metastatic Lung Cancer clinical trials
Below are recruiting metastatic lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,188 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07259226RecruitingPhase 2
Studying resistance to antibody-drug conjugates in advanced cancer
This study is for people with advanced breast, bladder, lung, or stomach cancer who are about to start treatment with a type of targeted therapy called an antibody-drug conjugate (ADC). The trial will collect tumor samples and blood to understand how cancers become resistant to these drugs and to find better ways to predict treatment success.
VillejuifAges 18 years+ - NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT07002177RecruitingPhase 1/Phase 2
Combination therapy study for ER+/HER2- breast cancer
This trial tests a new drug called FWD1802 combined with other treatments for people with a certain type of advanced breast cancer (ER-positive, HER2-negative). It aims to find better options if standard treatments have stopped working or aren't suitable.
ShanghaiAges 18–75 - NCT07314294RecruitingPhase 2
Study of EMB-01 for advanced left-sided colorectal cancer
This trial tests a new drug, EMB-01, in people with advanced left-sided colorectal cancer that has spread or cannot be removed. It may help if standard treatments have stopped working or caused side effects.
BeijingAges 18 years+ - NCT03449238RecruitingPhase 1/Phase 2
Pembrolizumab with focused brain radiation for breast cancer brain spread
This trial studies whether pembrolizumab (an immune therapy medicine) plus stereotactic radiosurgery (focused radiation) can better control brain metastases from breast cancer. It may help shrink or slow growth of multiple brain spots with minimal treatment to surrounding tissue.
New York, New YorkAges 19–90 - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+ - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for cancers with a KRAS G12D mutation
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06341595RecruitingPhase 2
Chemo, radiation and immunotherapy before surgery for stomach cancer with PALM
This trial tests combining chemotherapy, radiation, and an immunotherapy drug (sintilimab) before surgery for advanced stomach cancer that has spread to lymph nodes near the aorta (called PALM). The goal is to see if this approach can shrink the tumor enough to allow complete removal.
Nanjing, JiangsuAges 18–75 - NCT06190886RecruitingPhase 1
First-in-human study of PTX-912 for advanced solid tumors
This trial tests a new drug called PTX-912 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It is a first-in-human study, meaning this is the first time PTX-912 is being given to people, to see how safe it is and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT07423585RecruitingPhase 2
Tarlatamab for extensive stage small-cell lung cancer
This trial tests an experimental drug called tarlatamab for people newly diagnosed with extensive-stage small-cell lung cancer (SCLC). The goal is to see if tarlatamab can help shrink or control the cancer.
Columbus, OhioAges 18 years+ - NCT07250386RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06621563RecruitingPhase 1
Study of HS-20117 Combination Therapy for Advanced Solid Tumors
This early-phase trial tests a new drug (HS-20117) combined with other drugs for people with advanced solid tumors. It aims to see if the combination is safe and effective, especially for cancers that have not responded to other treatments.
TianjinAges 18–75 - NCT07044921RecruitingPhase 2
Irinotecan liposome combination for advanced colorectal cancer
This trial tests a new combination treatment for people with advanced colorectal cancer whose cancer has stopped responding to irinotecan. The goal is to see if adding a liposome form of irinotecan to other drugs can help shrink tumors or slow the disease.
BeijingAges 18 years+ - NCT06956690RecruitingPhase 1/Phase 2
Testing HMBD-501 for HER3-positive advanced solid tumors
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06839105RecruitingPhase 1
Testing AWT020 for advanced cancers
This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.
Fuzhou, FujianAges 18 years+ - NCT06764680RecruitingPhase 2
Oral drugs and radiation for advanced colorectal cancer after standard therapy
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18 years+ - NCT06618287RecruitingPhase 1/Phase 2
Testing BMS-986507 for advanced lung and breast cancers
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
Birmingham, AlabamaAges 18 years+ - NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
Duarte, CaliforniaAges 18 years+ - NCT06529081Recruiting
Radiation schedule for advanced small-cell lung cancer after chemo-immunotherapy
This study tests a specific radiation schedule (15 sessions to the chest and up to 3 sessions to other spots) for people with advanced small-cell lung cancer that responded to first-line chemo combined with immunotherapy. The goal is to see if this radiation approach can improve control of the disease.
LublinAges 18 years+ - NCT06389123RecruitingPhase 1
Targeted radiation for metastatic cancer that stopped responding
This study tests a new approach that first uses a special scan to find cancer cells that have a specific marker, then delivers targeted radiation to those cells. It is designed for people with advanced solid tumors that have spread and stopped responding to standard treatments.
Sacramento, CaliforniaAges 18 years+ - NCT05288205RecruitingPhase 1/Phase 2
JAB-21822 plus JAB-3312 for KRAS G12C solid tumors
This Phase 1/2a trial tests two investigational pills (JAB-21822 and JAB-3312) in people with advanced solid cancers that have a KRAS G12C mutation. It’s for cases where standard treatments have failed or aren’t suitable, to see if the drugs can shrink tumors and improve outcomes.
Hefei, AnhuiAges 18 years+ - NCT04339218RecruitingPhase 3
Cryoablation plus pembrolizumab and chemotherapy for lung cancer spread
This trial studies whether freezing a small number of lung cancer spots (cryoablation) alongside standard immunotherapy (pembrolizumab) and chemotherapy can improve outcomes in people with metastatic lung adenocarcinoma. It’s meant for people who have measurable tumors that can be safely targeted with the freezing treatment.
Bordeaux, GirondeAges 18 years+ - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Duarte, CaliforniaAges 18 years+
Hear when a new Metastatic Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic lung cancer?
- Yes. Clin2 currently lists 1,188 recruiting metastatic lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Metastatic Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.